Format
Sort by
Items per page

Send to

Choose Destination

Best matches for "tyrosine kinase" inhibitor:

Skin problems and EGFR-tyrosine kinase inhibitor. Kozuki T et al. Jpn J Clin Oncol. (2016)

Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma. de Rosamel L et al. Expert Opin Emerg Drugs. (2017)

BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Cuellar S et al. J Oncol Pharm Pract. (2018)

Search results

Items: 1 to 20 of 23637

1.

Protein kinase B mediates insulin-like growth factor 1-induced phosphorylation and nuclear export of histone deacetylase 5 via NADPH oxidase 4 activation in vascular smooth muscle cells.

Pietruczuk P, Jain A, Simo-Cheyou ER, Anand-Srivastava MB, Srivastava AK.

J Cell Physiol. 2019 Feb 22. doi: 10.1002/jcp.28353. [Epub ahead of print]

PMID:
30793765
2.

Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush.

Seki N, Ochiai R, Haruyama T, Ishihara M, Natsume M, Fukasawa Y, Sakamoto T, Tanzawa S, Usui R, Honda T, Ota S, Ichikawa Y, Watanabe K.

Case Rep Oncol. 2019 Jan 21;12(1):84-90. doi: 10.1159/000493256. eCollection 2019 Jan-Apr.

PMID:
30792647
3.

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.

Serrano C, Mariño-Enríquez A, Tao DL, Ketzer J, Eilers G, Zhu M, Yu C, Mannan AM, Rubin BP, Demetri GD, Raut CP, Presnell A, McKinley A, Heinrich MC, Czaplinski JT, Sicinska E, Bauer S, George S, Fletcher JA.

Br J Cancer. 2019 Feb 22. doi: 10.1038/s41416-019-0389-6. [Epub ahead of print]

PMID:
30792533
4.

Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation.

Chen YJ, Hsu CC, Shiao YJ, Wang HT, Lo YL, Lin AMY.

Sci Rep. 2019 Feb 21;9(1):2516. doi: 10.1038/s41598-019-38676-7.

PMID:
30792526
5.

Mouse-Derived Isograft (MDI) In Vivo Tumor Models II. Carcinogen-Induced cMDI Models: Characterization and Cancer Therapeutic Approaches.

Beshay J, Jantscheff P, Lemarchand T, Obodozie C, Schächtele C, Weber H.

Cancers (Basel). 2019 Feb 19;11(2). pii: E242. doi: 10.3390/cancers11020242.

PMID:
30791458
6.

A near-haploid clone harboring a BCR/ABL1 gene fusion in an adult patient with newly diagnosed B-lymphoblastic leukemia.

Peterson JF, Ketterling RP, Huang L, Finn LE, Shi M, Hoppman NL, Greipp PT, Baughn LB.

Genes Chromosomes Cancer. 2019 Feb 20. doi: 10.1002/gcc.22744. [Epub ahead of print]

PMID:
30790375
7.

Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations.

Nishio M, Murakami H, Ohe Y, Hida T, Sakai H, Kasahara K, Imamura F, Baba T, Kubota K, Hosomi Y, Shimokawa T, Hayashi H, Miyadera K, Tamura T.

Invest New Drugs. 2019 Feb 21. doi: 10.1007/s10637-019-00732-4. [Epub ahead of print]

PMID:
30790152
8.

Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient.

Hu Y, Xiao L, Yang N, Zhang Y.

Thorac Cancer. 2019 Feb 20. doi: 10.1111/1759-7714.13015. [Epub ahead of print]

PMID:
30788907
9.

Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis.

Arai K, Yoshifuji K, Motomura Y, Sonokawa S, Suzuki S, Kumagai T.

Int J Hematol. 2019 Feb 20. doi: 10.1007/s12185-019-02618-w. [Epub ahead of print]

PMID:
30788724
10.

Novel mechanism of resistance to targeted therapies in lung cancer.

Wang W, Carbone DP, Arasada RR.

Mol Cell Oncol. 2018 Dec 30;6(1):1551015. doi: 10.1080/23723556.2018.1551015. eCollection 2019.

PMID:
30788420
11.

Third-generation tyrosine kinase inhibitor in the treatment of epidermal growth factor receptor mutated squamous cell lung cancer: a tailored therapy approach.

Cortiula F, De Maglio G, Cangi MG, Gerratana L, Lisanti C, Bonura S, Fasola G, Follador A.

Ann Transl Med. 2019 Jan;7(1):14. doi: 10.21037/atm.2018.12.42.

PMID:
30788361
12.

Gastrointestinal stromal tumors: a comprehensive review.

Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH, Hinika GS.

J Gastrointest Oncol. 2019 Feb;10(1):144-154. doi: 10.21037/jgo.2018.08.20. Review.

PMID:
30788170
13.

Bivalent Ligands for Protein Degradation in Drug Discovery.

Scheepstra M, Hekking KFW, van Hijfte L, Folmer RHA.

Comput Struct Biotechnol J. 2019 Jan 25;17:160-176. doi: 10.1016/j.csbj.2019.01.006. eCollection 2019. Review.

PMID:
30788082
14.

Detection of EGFR mutations using target capture sequencing in plasma of patients with non-small-cell lung cancer.

Bai H, Xia J, Zhao X, Gong Z, Zhang D, Xiong L.

J Clin Pathol. 2019 Feb 20. pii: jclinpath-2019-205699. doi: 10.1136/jclinpath-2019-205699. [Epub ahead of print]

PMID:
30787028
15.

Checkpoint Inhibitor-TKI Combos Effective in RCC.

[No authors listed]

Cancer Discov. 2019 Feb 20. doi: 10.1158/2159-8290.CD-NB2019-024. [Epub ahead of print]

PMID:
30787015
16.

Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer.

Zhang J, Li Q, Wu Y, Wang D, Xu L, Zhang Y, Wang S, Wang T, Liu F, Zaky MY, Hou S, Liu S, Zou K, Lei H, Zou L, Zhang Y, Liu H.

Cell Commun Signal. 2019 Feb 20;17(1):15. doi: 10.1186/s12964-019-0328-4.

PMID:
30786890
17.

The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.

Huang X, Gan G, Wang X, Xu T, Xie W.

Autophagy. 2019 Feb 20:1-22. doi: 10.1080/15548627.2019.1580105. [Epub ahead of print]

PMID:
30786811
18.

Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.

Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ.

PLoS One. 2019 Feb 20;14(2):e0211228. doi: 10.1371/journal.pone.0211228. eCollection 2019.

19.

Involvement of gliadin, a component of wheat gluten, in increased intestinal permeability leading to non-steroidal anti-inflammatory drug-induced small-intestinal damage.

Shimada S, Tanigawa T, Watanabe T, Nakata A, Sugimura N, Itani S, Higashimori A, Nadatani Y, Otani K, Taira K, Hosomi S, Nagami Y, Tanaka F, Kamata N, Yamagami H, Shiba M, Fujiwara Y.

PLoS One. 2019 Feb 20;14(2):e0211436. doi: 10.1371/journal.pone.0211436. eCollection 2019.

20.

Tyrosine Kinase Inhibitor Associated Fibrothorax.

Adrianza AM, Jimenez CA, Aldana GL, Pozo L, Cortes JE, Sagar AES.

Am J Respir Crit Care Med. 2019 Feb 20. doi: 10.1164/rccm.201806-1155IM. [Epub ahead of print] No abstract available.

PMID:
30785770

Supplemental Content

Loading ...
Support Center